Supplementary Fig. 1 Antithrombin activity measurements in patients with rivaroxaban. (A) Correlation between antithrombin (AT) activity determined by a thrombin inhibition–based assay (ATFIIa) and a factor Xa inhibition–based assay (ATFXa) in samples from patients with suspected thrombophilia (n = 86, black symbols). Red symbols represent data obtained from patients with mutations in the SERPING1 gene. Grey lines indicate the reference ranges of ATFIIa (79.4–112.0%) and ATFXa (82.9–118.2%). (B) Bland–Altman plot for ATFIIa and ATFXa.

Supplementary Fig. 2 Antithrombin activity measurements in patients with apixaban. (A) Correlation between antithrombin (AT) activity determined by a thrombin inhibition–based assay (ATFIIa) and a factor Xa inhibition–based assay (ATFXa) in samples from patients without hereditary AT deficiency (n = 72). (B) Bland–Altman plot for ATFIIa and ATFXa.

Supplementary Fig. 3 Antithrombin activity/antigen ratio. Box whisker plots of the ratio of antithrombin activity divided by antithrombin antigen level (AT/ATAg). The central horizontal line is drawn at the median. Top and bottom edges of the boxes are located at the 75th and 25th percentiles. Top and bottom of the whiskers are located at the 90th and 10th percentiles.